Ex-Quince IRulya funds inhaled rapamycin trials into 2028 as first data nears
Rebranded as IRulya and trading on Nasdaq as IRLA, the company says its $105.2m cash balance covers its LAM-001 studies, with the first Phase 2 results due early next year.
IRulya Therapeutics, the business previously known as Quince Therapeutics, has told investors it holds $105.2m in cash and expects that sum to finance operations through 2028. The disclosure came with its third-quarter 2026 results on 13 November.
The money is tied to a single asset. The company's pipeline now rests on LAM-001, an inhaled form of rapamycin. Its first test is a Phase 2 study in bronchiolitis obliterans syndrome (BOS) after lung transplant, with results guided for the first quarter of 2027. A second Phase 2 trial, in pulmonary hypertension linked to interstitial lung disease (PH-ILD), is expected to report in the first quarter of 2028.
IRulya also intends to run a study in sarcoidosis-associated pulmonary hypertension. The material available gives no further detail on that trial, including its timing or design.
The company changed its name and began trading on Nasdaq under the ticker IRLA in October 2026. No Phase 2 results for LAM-001 have been reported so far, and the information provided includes no revenue, pricing or partnership figures, so the programme's commercial value cannot yet be assessed.
Why it matters
- With cash guided to last through 2028, IRulya says it can fund both Phase 2 readouts, the first in Q1 2027 and the second in Q1 2028, without a stated need to raise capital before then.
- The company's value hinges on one inhaled rapamycin asset, so the early-2027 BOS data will be the first real test of the programme.
- LAM-001 targets transplant and pulmonary vascular indications, but no efficacy data, regulatory path or commercial terms have been disclosed.
- Anyone tracking the former Quince Therapeutics should now use IRulya Therapeutics and the Nasdaq ticker IRLA.
Company's press release (SEC filing): IRulya Therapeutics Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
Cerenome reports first CNSide revenue and completes enrolment in Phase 2 glioblastoma trial
BeyondSpring wins FDA Fast Track for plinabulin plus docetaxel in post-immunotherapy NSCLC
Valneva: 94% of adults still seroresponders five years after single IXCHIQ dose
GH Research posts $46.6M nine-month loss as GH001 depression programme nears pivotal stage
FDA lifts ARD-101 clinical hold in Prader-Willi; Aardvark to run open-label trial
